Aether oil and gas became largest Q2 FY27 revenue segment

Aether’s oil and gas segment became its largest in Q2 FY27, contributing 33.4% of consolidated revenue versus 18.8% in Q2 FY26. Pharmaceuticals fell to 26.6% from 36.6%, reversing the order of the two biggest end markets. The same ranking appeared in H1 FY27, with oil and gas at 32.4%.

How did Aether’s Q2 FY27 revenue mix change?

Aether increased oil and gas’s Q2 FY27 revenue contribution by 14.6 percentage points year on year, to 33.4% from 18.8%, while pharmaceuticals declined by 10.0 percentage points to 26.6% from 36.6%. Oil and gas therefore led pharmaceuticals by 6.8 percentage points in Q2 FY27, after trailing it by 17.8 percentage points in Q2 FY26.

The two largest end markets together accounted for 60.0% of Q2 FY27 revenue, compared with 55.4% a year earlier. That 4.6-percentage-point increase came despite the decline in pharmaceuticals’ share, because oil and gas added more share than pharmaceuticals lost.

Which segments followed oil and gas in Q2 FY27?

Aether’s pharmaceuticals segment ranked second in Q2 FY27 at 26.6%, followed by material science at 17.9% and agrochemicals at 7.9%. Those four segments represented 85.8% of Q2 FY27 revenue, compared with 88.1% in Q2 FY26, when pharmaceuticals was the largest contributor and oil and gas ranked third.

Material science remained third despite its contribution falling 1.5 percentage points from 19.4% in Q2 FY26. Agrochemicals recorded the largest decline outside the two leading segments, dropping 5.4 percentage points from 13.3% to 7.9%.

Among smaller categories, multiple increased to 6.5% in Q2 FY27 from 5.6% a year earlier. Sustainability and renewables increased to 2.1% from 1.1%, while coatings rose to 1.6% from 1.0%; high performance photography declined slightly to 4.0% from 4.2%.

Did oil and gas remain the largest segment in H1 FY27?

Aether’s H1 FY27 figures also put oil and gas first, at 32.4% of revenue, ahead of pharmaceuticals at 29.3%. In H1 FY26, pharmaceuticals contributed 35.8% and oil and gas contributed 19.0%, showing that the quarterly change was also reflected across the first half.

Oil and gas gained 13.4 percentage points in H1 FY27 versus H1 FY26, while pharmaceuticals lost 6.5 percentage points. Q2 FY27 was modestly more concentrated in oil and gas than the first-half average, as its 33.4% share was 1.0 percentage point above the H1 FY27 level.

Pharmaceuticals’ 26.6% Q2 FY27 share was 2.7 percentage points below its H1 FY27 contribution of 29.3%. Material science was broadly stable at 17.9% in H1 FY27 versus 18.2% in H1 FY26, while agrochemicals declined to 8.6% from 12.2%.

High performance photography fell to 3.6% of H1 FY27 revenue from 5.7% in H1 FY26. Sustainability and renewables increased to 1.9% from 1.5%, whereas coatings declined to 1.6% from 2.1% over the same half-year comparison.

What does Aether say is behind the revenue mix shift?

Aether says oil and gas and material science are expected to be its main drivers, despite new-product launches in pharmaceuticals and agrochemicals. The presentation also says CEM contracts are being negotiated with clients across sectors, without disclosing the revenue value, customer, product or timing of any individual contract.

Aether describes a business-model pivot towards CEM contracts and CRAMS as contributing to operating-income and margin growth. In Q2 FY27, earnings before interest, taxes, depreciation and amortisation, or EBITDA, was Rs 110.4 crore, with a 31.8% margin, compared with Rs 85.3 crore and a 30.5% margin in Q2 FY26.

Q2 FY27 EBITDA was also above Rs 102.8 crore in Q1 FY27, when the EBITDA margin was 31.5%. The presentation links the performance to the CEM and CRAMS business models, but does not allocate the Rs 25.1 crore year-on-year EBITDA increase among oil and gas, material science or other end markets.

How did profitability and research spending develop alongside the mix?

Aether reported profit after tax, or PAT, of Rs 68 crore in Q2 FY27, with a 19.3% margin, compared with Rs 54 crore and an 18.7% margin in Q2 FY26. The presentation attributes the higher Q2 FY27 profitability to a shift in segment mix.

For H1 FY27, operating revenue was Rs 673.8 crore, up 27% from Rs 531.2 crore in H1 FY26. EBITDA increased 30% to Rs 213.2 crore and its margin rose to 31.6% from 30.8%, while PAT increased 29% to Rs 130.7 crore and its margin rose to 19.0% from 18.6%.

Aether spent Rs 40.601 crore on research and development in H1 FY27, equal to 6.03% of revenue from operations. It said its research and development expansion was on track, with 18 fume hoods installed and construction under way on a new research and development building.

Ground-levelling work at Catalyst Site 1 had been completed, and Aether said building construction was expected to be completed by Q1 FY28. The presentation does not state how much of the H1 FY27 research and development spending is associated with Catalyst Site 1 or any particular end-market segment.

Conclusion

Aether’s segment data show that oil and gas replaced pharmaceuticals as the largest revenue exposure in Q2 FY27, with a 33.4% share against pharmaceuticals’ 26.6%. The H1 FY27 ranking confirms that the change extended beyond one quarter, while the company reported higher operating revenue, EBITDA, PAT and margins across the first-half comparison.

The next items to watch are management’s stated expectation that oil and gas and material science will be main drivers, negotiations of CEM contracts across sectors, and new-product launches in pharmaceuticals and agrochemicals. Aether also expects the Catalyst Site 1 research and development building to be completed by Q1 FY28.